Reading HAE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HAE free→Reading HAE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HAE free→QuarterlyIQ Insights · HAE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). Mr. Dockendorff has served as a member of the Board of Directors (the “Board”) of the Company since 2014 and currently serves as a member…
Regulation FD Disclosure. On March 2, 2026, Haemonetics Corporation (the “Company”) repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 (the “Notes”). The Company paid an aggregate amount of $300,000,000 in cash, representing the outstanding principal amount of the Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the Notes prior to the close of b…
Results of Operations and Financial Condition. On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.